(NASDAQ: LAB) Standard Biotools's forecast annual revenue growth rate of 35.69% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 6%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.3%.
Standard Biotools's revenue in 2024 is $106,340,000.On average, 2 Wall Street analysts forecast LAB's revenue for 2024 to be $58,444,256,999, with the lowest LAB revenue forecast at $58,023,586,000, and the highest LAB revenue forecast at $58,864,927,997. On average, 3 Wall Street analysts forecast LAB's revenue for 2025 to be $58,787,466,510, with the lowest LAB revenue forecast at $42,473,264,952, and the highest LAB revenue forecast at $68,032,654,585.
In 2026, LAB is forecast to generate $50,683,602,371 in revenue, with the lowest revenue forecast at $50,683,602,371 and the highest revenue forecast at $50,683,602,371.